Loading…
Odyssey Therapeutics, Inc. is projected to rise to $22.51 by 2027, a +43% move from its current price of $15.70. Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $15.19 | $15.71 | $16.25 | +0.06% |
| Jul 14 | $14.98 | $15.72 | $16.49 | +0.12% |
| Jul 15 | $14.83 | $15.73 | $16.68 | +0.19% |
| Jul 16 | $14.71 | $15.74 | $16.84 | +0.25% |
| Jul 17 | $14.60 | $15.75 | $16.99 | +0.31% |
| Jul 18 | $14.50 | $15.76 | $17.12 | +0.37% |
| Jul 19 | $14.41 | $15.77 | $17.25 | +0.43% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $14.41 | $15.77 | $17.25 | +0.43% |
| Week 2 | $13.95 | $15.84 | $17.98 | +0.87% |
| Week 3 | $13.61 | $15.91 | $18.58 | +1.31% |
| Week 4 | $13.35 | $15.97 | $19.12 | +1.75% |
| Week 5 | $13.12 | $16.04 | $19.61 | +2.19% |
| Week 6 | $12.93 | $16.11 | $20.08 | +2.63% |
| Week 7 | $12.76 | $16.18 | $20.52 | +3.08% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Odyssey Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops medicines for autoimmune and inflammatory diseases. The company pipeline includes OD-001, an oral small molecule inhibitor of receptor-interacting protein kinase 2, which is in phase 2a trial for the treatment of ulcerative colitis; OD-002, an oral small molecule SLC15A4 inhibitor designed to block TLR7/8/9-mediated pathogenic inflammatory responses activation of interferon regulatory factor 5 (IRF5); OD-003, a protein therapeutic designed to agonize tumor necrosis factor receptor 2 selectively on Treg; a TSLP/IL-33 bispecific antagonist; an oral small molecule interleukin-1 receptor-associated kinase 4 scaffolding inhibitor; and a small molecule inhibitor of IRF5.
The company was incorporated in 2021 and is headquartered in Boston, Massachusetts.
Odyssey Therapeutics, Inc. (ODTX) operates in Healthcare as a clinical-stage biopharmaceutical company focused on medicines for autoimmune and inflammatory diseases. The stock is currently priced at $16.61 per share and has a market cap of $797.8M, ranking 2733.
The near-term price outlook is informed by a year-by-year forecast showing a path of growth beyond 2026, with meaningful upside by the late 2020s and into the 2030s and beyond.
A major floor 13.4% below — a decisive break under it would weaken the trend.
Price is testing support right now (0.9% away) — a key level to hold.
The nearest ceiling, 21.5% above — a clean break opens room to run.
A major ceiling 31.3% above — clearing it would confirm fresh momentum.
Key ODTX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ODTX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $16.29 | Sell | $16.57 | Sell |
| MA 10 | $17.05 | Sell | $16.87 | Sell |
| MA 20 | $17.54 | Sell | $17.17 | Sell |
| MA 50 | — | Neutral | — | Neutral |
| MA 100 | — | Neutral | — | Neutral |
| MA 200 | — | Neutral | — | Neutral |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 46.68 | Neutral |
| Stoch RSI (14) | 36.08 | Neutral |
| CCI (20) | -61.09 | Neutral |
| Williams %R (14) | -66.07 | Info |
| MACD (12,26,9) | -0.21 | Sell |
| ROC (12) | -10.03 | Sell |
| Bollinger %B (20,2) | 0.29 | Neutral |
| Stochastic %K (14) | 33.93 | Neutral |
| TRIX (15) | — | Neutral |
| Awesome (5,34) | -1.07 | Sell |
| Ultimate (7,14,28) | 33.60 | Neutral |
| Momentum (10) | -1.11 | Sell |
| Aroon Osc (25) | -48.00 | Sell |
| Hull MA (9) | 15.96 | Sell |
| ADX (14) | 14.29 | Neutral |
| ATR (14) | 0.52 | Info |
In the near term, sentiment is NEUTRAL and the RSI(14) is 40. The 30-day range extends from $13.22 to $20.88, with technical support at $16.20 and resistance at $19.07. The SMA50 and SMA200 figures are not provided in the data.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $15.56 | $15.70 | $23.58 | 0% | Neutral | |
| $16.48 | $22.51 | $33.21 | +43% | Bullish | |
| $20.27 | $29.32 | $45.98 | +87% | Bullish | |
| $21.11 | $32.06 | $52.71 | +104% | Bullish | |
| $21.74 | $34.52 | $59.00 | +120% | Bullish | |
| $21.29 | $35.23 | $62.26 | +124% | Bullish | |
| $22.01 | $37.89 | $68.98 | +141% | Bullish | |
| $25.58 | $45.72 | $85.48 | +191% | Bullish | |
| $29.84 | $55.31 | $105.96 | +252% | Bullish | |
| $32.87 | $63.16 | $123.71 | +302% | Bullish | |
| $39.63 | $88.07 | $189.13 | +461% | Bullish | |
| $79.21 | $176.03 | $404.86 | +10.2x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $15.56 | $15.70 | $19.87 | +0.00% |
| August 2026 | $13.97 | $16.89 | $21.24 | +7.58% |
| September 2026 | $13.56 | $16.61 | $21.31 | -1.66% |
| October 2026 | $13.53 | $16.76 | $21.86 | +0.91% |
| November 2026 | $14.06 | $17.59 | $23.26 | +4.95% |
| December 2026 | $13.94 | $17.61 | $23.58 | +0.08% |
Click any year to see its month-by-month ODTX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Odyssey Therapeutics, Inc.'s 2026 outlook centres on $15.70, within a $15.56 to $23.58 range. That marks a 0% change versus current levels. Price action looks broadly range-bound.
By 2027, ODTX could reach as high as $33.21, with a base case around $22.51 and support toward $16.48 — roughly +43% from $15.70. Buyers look set to stay in control over this stretch.
Expect ODTX to range from $20.27 to $45.98 through 2028. The $29.32 average target implies a +87% move from current prices. That is up +30% on the projected 2027 average. Momentum favours further upside here.
The ODTX price prediction for 2029 points to an average of $32.06 (low $21.11, high $52.71) — a potential gain of +104% on today's $15.70. Buyers look set to stay in control over this stretch.
In 2030, ODTX is projected to trade between $21.74 and $59.00, averaging $34.52 — a potential gain of +120% from today's $15.70. That is up +8% on the projected 2029 average. Momentum favours further upside here.
Odyssey Therapeutics, Inc.'s 2031 outlook centres on $35.23, within a $21.29 to $62.26 range. That is up +2% on the projected 2030 average. That marks a +124% change versus current levels. Buyers look set to stay in control over this stretch.
By 2032, ODTX could reach as high as $68.98, with a base case around $37.89 and support toward $22.01 — roughly +141% from $15.70. Momentum favours further upside here.
Expect ODTX to range from $25.58 to $85.48 through 2033. The $45.72 average target implies a +191% move from current prices. That is up +21% on the projected 2032 average. Buyers look set to stay in control over this stretch.
The ODTX price prediction for 2034 points to an average of $55.31 (low $29.84, high $105.96) — a potential gain of +252% on today's $15.70. Momentum favours further upside here.
In 2035, ODTX is projected to trade between $32.87 and $123.71, averaging $63.16 — a potential gain of +302% from today's $15.70. That is up +14% on the projected 2034 average. Buyers look set to stay in control over this stretch.
Odyssey Therapeutics, Inc.'s 2040 outlook centres on $88.07, within a $39.63 to $189.13 range. That is up +39% on the projected 2035 average. That marks a +461% change versus current levels. Momentum favours further upside here.
By 2050, ODTX could reach as high as $404.86, with a base case around $176.03 and support toward $79.21 — roughly +10.2x from $15.70. Buyers look set to stay in control over this stretch.
Investing $1,000 in ODTX today (≈ 63.694268 ODTX) could be worth
$11,211.96
+$10,211.96 (+1021%) by 2050 · US Dollar
Based on the average projected ODTX price of $176.03 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ODTXwould be worth at today's price.
$1,000 invested in ODTX on May 8, 2026 (≈ 60.90134 ODTX) would be worth
$956.15
-$43.85 (-4.4%) today · 0.96× · US Dollar
Based on a ODTX entry price of $16.42 vs. today's $15.7.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $16.8 | $934.52 | -6.5% |
| 1 month ago | $16.2 | $969.14 | -3.1% |
| All time ago | $16.42 | $956.15 | -4.4% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ODTX forecast.
Our base-case forecast reaches $31.00 around 2029.
Implied market cap at $31.00: $1.49B
The multi-year forecast depicts a bullish trajectory starting in 2027, with the average price rising from $24.06 in 2027 to $184.27 by 2050 and the max price climbing to $423.81 in 2050. The forecast shows 2027 avg $24.06 (ROI 44.8), 2028 avg $31.70 (ROI 90.9), 2029 avg $33.79 (ROI 103.4), 2030 avg $36.68 (ROI 120.8), 2031 avg $37.79 (ROI 127.5), 2032 avg $39.77 (ROI 139.5), 2033 avg $49.10 (ROI 195.6), 2034 avg $59.35 (ROI 257.3), 2035 avg $66.42 (ROI 299.9), 2040 avg $94.77 (ROI 470.6), and 2050 avg $184.27 (ROI 1009.4). The years 2026 onward show bullish sentiment, with a neutral starting point in 2026 (min $16.20, avg $16.61, max $24.87; ROI 0).
These are estimates and not guarantees, and biotech equities carry substantial risk alongside potential upside.
Tap a question to reveal the answer.
In 2030 the forecast shows an average price of $36.68, a min of $22.89 and a max of $63.17, with a potential ROI of 120.8% and a bullish sentiment.
Forecasts show a bullish path from 2027 onward, with the 2027 average price at $24.06 and a 2027 ROI of 44.8%, rising to $184.27 average by 2050 and a 1009.4% ROI. The 2026 figures are neutral (avg $16.61, ROI 0). This is not financial advice and carries biotech risks.
Yes. The forecast max price exceeds $100 starting in 2034, with a max of $114.71 in 2034, and it climbs to $205.60 by 2040 and $423.81 by 2050.
The 2027 forecast shows an average price of $24.06, a min of $17.51, a max of $35.72, with a predicted ROI of 44.8% and bullish sentiment.
Odyssey Therapeutics, Inc. Community Discussion
0Share your Odyssey Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.